Graphene Oxide Based Theranostic Platform for <i>T</i>₁‑Weighted Magnetic Resonance Imaging and Drug Delivery

Magnetic resonance imaging (MRI) is a powerful and widely used clinical technique in cancer diagnosis. MRI contrast agents (CAs) are often used to improve the quality of MRI-based diagnosis. In this work, we developed a positive <i>T</i>₁ MRI CA based on graphene oxide (GO)–gadolinium (Gd) complexes. In our strategy, diethylenetriaminepentaacetic acid (DTPA) is chemically conjugated to GO, followed by Gd­(III) complexation, to form a <i>T</i>₁ MRI CA (GO–DTPA–Gd). We have demonstrated that the GO–DTPA–Gd system significantly improves MRI <i>T</i>₁ relaxivity and leads to a better cellular MRI contrast effect than Magnevist, a commercially used CA. Next, an anticancer drug, doxorubicin (DOX), was loaded on the surface of GO sheets via physisorption. Thus-prepared GO–DTPA–Gd/DOX shows significant cytotoxicity to the cancer cells (HepG2). This work provides a novel strategy to build a GO-based theranostic nanoplatform with <i>T</i>₁-weighted MRI, fluorescence imaging, and drug delivery functionalities